A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose in mg/m2 based on the dose-limiting adverse events that occur
First cycle (expected to be 21 days, including the day of first dose of tesetaxel followed by a rest period)
Yes
United States: Food and Drug Administration
TOPK106
NCT01337310
April 2011
September 2012
Name | Location |
---|